Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciad694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von L Mikiashvili und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Nitroimidazoles, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCATS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
There are scarce data on the clinical outcomes of persons retreated with new/companion anti-tuberculosis (TB) drugs for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We sought to evaluate the efficacy and safety of bedaquiline and delamanid containing regimens among patients with and without prior exposure to the new/companion drugs (bedaquiline, delamanid, linezolid, clofazimine, and fluoroquinolones).
Methods
We conducted a retrospective cohort study among patients with pulmonary MDR/RR-TB in Georgia who received bedaquiline and delamanid combination as a part of a salvage regimen from November 2017 to December 2020 in a programmatic setting.
Results
Among 106 persons with a median age of 39.5 years, 44 (41.5%) were previously treated with new/companion TB drugs. Patients with prior exposure to new/companion drugs had higher rates of baseline resistance compared to those without exposure to new/companion TB drugs (bedaquiline 15.2% vs 1.8%, linezolid 22.2% vs 16.7%). Sputum culture conversion rates among patients exposed and not exposed to new/companion drugs were 65.9% vs 98.0%, respectively (P < .001). Among patients with and without prior new/companion TB drug use, favorable outcome rates were 41.0% and 82.3%, respectively (P < .001). Treatment adherence in 32 (30.2%) patients was ≤80%. Five of 21 patients (23.8%) who had a baseline and repeat susceptibility test had acquired bedaquiline resistance. QTC/F prolongation (>500 ms) was rare (2.8%).
Conclusions
Prior exposure to new/companion TB drugs was associated with poor clinical outcomes and acquired drug resistance. Tailoring the TB regimen to each patient's drug susceptibility test results and burden of disease and enhancing adherence support may improve outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
- Department of Medicine, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia, USA.
- School of Public Health, Georgia State University, Atlanta, Georgia, USA.
- Department of Medicine, David Tvildiani Medical University, Tbilisi, Georgia.
- Department of Medicine, The University of Georgia, Tbilisi, Georgia.
ORCID-Profile: R R Kempker
Förderung
- NIA NIH HHS
- NCATS NIH HHS
- NIAID NIH HHS
- FIC NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Fogarty International Center
Zitieren
APA
Mikiashvili, L., Kempker, R. R., Chakhaia, T. S., Bablishvili, N., Avaliani, Z., Lomtadze, N., Schechter, M. C., & Kipiani, M. (2024). Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad694
Vancouver
Mikiashvili L, Kempker RR, Chakhaia TS, Bablishvili N, Avaliani Z, Lomtadze N, et al. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad694
BibTeX
@article{Mikiashvili2024,
author = {Mikiashvili, L and Kempker, R R and Chakhaia, T S and Bablishvili, N and Avaliani, Z and Lomtadze, N and Schechter, M C and Kipiani, M},
title = {Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciad694}
}
EUVIMED